The latest update is out from BerGenBio ASA ( (BRRGF) ).
BerGenBio ASA has engaged Carnegie AS as its financial advisor to explore strategic alternatives, which may include acquisitions, mergers, or other transactions. The company has also implemented significant cost-containment and cash conservation measures to support its operations during this strategic review.
More about BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, with a subsidiary in Oxford, UK. The company is focused on developing transformative drugs targeting AXL kinase as a potential cornerstone therapy for aggressive diseases, including cancer. BerGenBio is listed on the Oslo Stock Exchange under the ticker BGBIO.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.54M
For a thorough assessment of BRRGF stock, go to TipRanks’ Stock Analysis page.